Skinvisible Granted US Patent for Topical Drug Delivery Technology
Invisicare(R) Patent Protection Extends to Year 2029
Skinvisible Pharmaceuticals, Inc. ( OTCQB : SKVI ) ( OTCBB : SKVI ) today announced that it has been granted US Patent Number 8,318,818 for methods of manufacturing its topical drug delivery technology, Invisicare®. The patent issued by the United States Patent and Trademark Office (USPTO) entitled “Topical Composition, Topical Composition Precursor, and Methods For Manufacturing and Using,” will provide protection for Invisicare until February 2029. This is one of a series of three patents granted in the United States specifically protecting Invisicare. This patent is a divisional patent stemming from Skinvisible’s main US patent and follows an announcement last week of the granting of a separate US patent for retinoids made with Invisicare.
This patent further protects the composition of Invisicare; a delivery technology used to bind active ingredients to the skin. Other key benefits include controlling the release of active ingredients and decreasing skin irritation. The patent covers a vast array of skin treatments including anti-acne, antifungals, anti-inflammatory, antimicrobials or any drug delivered to the skin with Invisicare. Additionally, skincare products such as anti-aging formulations, sunscreens and moisturizers have extended protection with the granting of this patent.
“The granting of this latest patent is fundamental to our intellectual property portfolio for Invisicare. Our products become highly desirable when you can provide new benefits to products and protect them from duplication in the marketplace as Invisicare can,” said Terry Howlett, President and CEO. “Our patents increase the value of Skinvisible as a company and provide our potential licensees with a strong competitive position in the dermatology, skincare and topical drug marketplace.” He added, “We expect our increased patent protection will assist us greatly in our discussions with potential licensees of our products.”
Skinvisible’s intellectual property portfolio for Invisicare includes: U.S.(3), Canada, Europe(4), Australia, India, Japan, China, Hong Kong and S. Korea along with three product specific US patents covering its dermal barrier products, sunscreen formulations and retinoids. Skinvisible is focused on strengthening its global patent portfolio with a number of patents pending for Invisicare as well as its forty plus prescription, over-the-counter and cosmeceutical formulations it has developed.
About Skinvisible Pharmaceuticals, Inc.
Skinvisible Pharmaceuticals is a research-and-development company that licenses its proprietary formulations made with Invisicare, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time resisting both wash off and perspiration along with controlling the release of actives and reducing skin irritation. Skinvisible receives a combination of license fees, and ongoing royalties for its licensed product formulations. Skinvisible’s value also lies in its ability to continually generate new IP on topical products formulated with Invisicare. www.skinvisible.com and www.invisicare.com.
Forward-Looking Statements: This press release contains ‘forward looking’ statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10Q for the quarter ending September 30, 2012).
Contact:
Corporate
Doreen McMorran
Skinvisible Pharmaceuticals, Inc.
Phone: 702-433-7154
Email: [email protected]
StockGuru is STOCKGURU.COM. 1601 Berwick Drive, McKinney, Texas 75070 – (469) 252-3030. Disclosure: StockGuru has covered SKVI before for compensation, however, today we are covering this release due to the recent activity in the stock and the significance of the news. StockGuru entered into an investor relations consulting and market awareness contract on July 12, 2010. The company paid us five thousand dollars per month in cash for the period one month. StockGuru was previously compensated 500,000 144 restricted common shares by the company for profile coverage for the period ending January 30, 2010. To avoid all potential conflicts of interest, we never sell shares into the open market during an active market awareness or investor relations program. This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we are not selling shares at the same time. We hold no shares and will not be receiving further compensation that is share related during this period. StockGuru is not a registered investment adviser or a broker/dealer. StockGuru makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.